



July 5, 2006

PROTANDIM® FEATURED IN PROGRAM AIRING ON PBS STATIONS

DENVER, Colorado – Lifeline Therapeutics, Inc. (OTCBB: LFLT), maker of Protandim®, today announced broadcast times for the Cellular Health segment featuring Protandim® in Healing Quest's episode #302.

The episode first aired in New York on WLIW-TV. Future showings include:

Sunday, July 9 - 4:30 p.m. on KLRN-TV in San Antonio;

Sunday, July 9 - 11:30 a.m. on WCNY-TV and WCNY-TV Digital in Syracuse;

Sunday, July 9 - 4:00 p.m. on WCFE-TV in Burlington, VT/Plattsburgh, NY;

Sunday, July 9 - 12:30 p.m. on KRWG-TV in El Paso;

Wednesday, July 12 - 9:30 a.m. and 5:30 p.m. on WCNY-2 in Syracuse;

Saturday, July 15 - 2:30 p.m. on WVIA-TV in Scranton/Wilkes Barre;

Tuesday, July 18 - 2:30 p.m. on WQED-TV in Pittsburgh;

Wednesday, July 19 - 11:30 a.m. on KBDI-TV in Denver; and

Saturday, July 29 - 5:30 p.m. on WEIU-TV in Springfield/Champaign, IL.

This initial broadcast list is based on information posted on station websites and on established broadcast patterns of stations that have made *Healing Quest* a regular part of their program schedule. All dates are subject to change by each station.

Viewers contacting *Healing Quest* for more information about Protandim® are directed to the Protandim® website or to the *Healing Quest* website with a link to the Protandim® website.

Stephen K. Onody, CEO of Lifeline Therapeutics, commented, "I am pleased at the initial number of stations scheduled to air the program featuring Protandim®, a patent-pending dietary supplement that increases the body's natural antioxidant defenses and combats oxidative stress."

About Healing Quest

Healing Quest is a national weekly TV series focused entirely on the latest in integrative health and natural approaches to total well-being. Its goal is to provide accessible, well-researched information on the new choices available to help achieve optimum well-being for mind, body and spirit. For more information, please visit the website at www.healingquest.tv.

About Protandim®

Protandim® is a patent-pending dietary supplement that increases the body's natural antioxidant protection by inducing two protective enzymes, superoxide dismutase (SOD) and catalase (CAT). These naturally occurring enzymes simply become overwhelmed by free radicals as we get older. Oxidative stress (cell damage caused by free radicals) occurs as a person ages, when subjected to environmental stresses or as an associated factor in certain illnesses. TBARS are laboratory markers for oxidative stress in the body. New data from a scientific study in men and women show that after 30 days of taking Protandim®, the level of circulating TBARS decreased an average of 40 percent, with this decrease shown to be maintained at 120 days. Protandim® strengthens a person's defenses against oxidative stress by increasing the body's natural antioxidant enzymes. For more information, please visit the Protandim® product web site at www.protandim.com.

About Lifeline Therapeutics, Inc.

Lifeline Therapeutics, Inc. markets Protandim®. Lifeline Therapeutics is committed to helping people achieve health and wellness for life. For more information, please visit the Company's web site at www.lifelinetherapeutics.com.

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences include the Company's limited cash flow and the rapid development of technology, lack of liquidity for the Company's common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.

#

CONTACTS:

Lifeline Therapeutics, Inc

Stephen K. Onody, CEO

Phone: 720-488-1711

Gerald J. Houston, CFO

Fax: 303-565-8700